EPA/DHA dietary supplementation attenuates exercise-induced bronchoconstriction in physically active asthmatic males

Figures & data

Table 1. Participant characteristics

Characteristics	Measurement (n = 9)
Stature (m)	1.8 ± 0.1
Age (years)	21.0 ± 0.9
Weight (kg)	74.4 ± 2.0
FEV1/FVC	77 ± 1.4
Predicted FEV1/FVC (%)	101.8 ± 3.4
Predicted FEV1	84.8 ± 1.2
FEF 25–75 (l/s)	4.9 ± 0.1
PEF (l/min)	574 ± 28.7
FeNO (ppb)	52.1 ± 3.7

Notes: FEV₁ = Forced Expiratory Volume in 1 s, FVC = Forced Vital Capacity, PFT = Peak Expiratory Flow, FEF 25–75% = Forced Expiratory Flow.

Values are mean ± SEM and were recorded before exercise challenge test.

Figure 1. The percentage change in FEV₁ before and after exercise at baseline, placebo and omega-3 (EPA/DHA) phase for all participants. Reduction in FEV₁ > 10% shows a positive diagnosis for EIB.

*Significant improvement from baseline (p < 0.05).

Figure 2. Fatty acid content for EPA, DHA and AA expressed as a percentage (%) of total fatty acid content.

Figure 3. Serum levels of IL-6 at different time points of the study.

*p < 0.05, significant difference in IL-6 level after omega-3 supplementation compared to baseline. Data shown as mean ± SEM.